Innovation and Leadership in Engineering Technologies and Therapies for Diabetes

糖尿病工程技术和治疗的创新和领导地位

• 批准号: 8545173
• 负责人: JULIA E BABENSEE
• 金额: $ 7.19万
• 依托单位: GEORGIA INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-17 至 2015-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8545173
• 关键词: Academia; Affect; Area; Artificial Pancreas; Autologous; Beta Cell; Biocompatible Materials; Biological; Biomedical Engineering; Biotechnology; Caring; Cell Therapy; Cells; Clinical; Complex; Development; Diabetes Mellitus; Economic Burden; Encapsulated; Engineering; Engraftment; Exposure to; Generations; Glucose; Health; Health Care Costs; Hydrogels; Immune; Industry; Injection of therapeutic agent; Institutes; Insulin; Insulin Infusion Systems; Insulin-Dependent Diabetes Mellitus; Joints; Leadership; Life; Methods; Microfabrication; Patient Care; Patients; Physiological; Population; Positioning Attribute; Process; Protocols documentation; Quality of life; Research; Research Training; Sampling; Science; System; Technology; Tissues; Training; Training Programs; Transplantation; Universities; abstracting; base; beta cell replacement; blood glucose regulation; commercialization; diabetes management; diabetes mellitus therapy; diabetic; improved; innovation; islet; islet allograft; islet xenograft; medical schools; next generation; non-invasive monitor; novel; post-doctoral training; programs; translational medicine

Abstract The Diabetes Program: innovation & Leadership in Engineering Technologies and Therapies (ILET^) is a unique, cross-disciplinary postdoctoral training program in cell- and tissue-based therapies and novel insulin delivery technologies for insulin-dependent diabetes (IDD). IDD is a significant health problem affecting millions of people in the U.S and worldwide. Compared to current treatments based on insulin injections or open-loop insulin pumps, new generation therapies have the potential to provide a less invasive, more physiologic and ultimately less costly regulation of blood glucose levels, potentially reducing long-term complications and revolutionizing diabetes care. There is a critical need for cross-disciplinary training of bioengineers and bioscientists in the complex problems relating to developing living biological substitutes for beta cell replacement and the artificial pancreas, which encompass fundamental science, bioengineering and translational medicine. ILET^ is a joint training program between the Georgia Institute of Technology and Emory University School of Medicine. This program will train the future research experts in this field by providing trainees with expertise in the following areas critical to advancing the next generation therapies for diabetes: 1) the ability to develop new islet encapsulation and engraftment systems, including new biomaterials and processes; 2) the ability to engineer immune acceptance of islet allografts and xenografts; 3) the ability to engineer non-beta insulin- secreting, physiologically responsive cells as an alternative to islets; and 4) the ability to develop new methods for glucose sampling and insulin delivery towards a closed loop artificial pancreas system. Research-based training in cell-based therapies will specialize in encapsulated systems for islets and other insulin-secreting cells; the engineering of potentially autologous beta cell surrogates; the development of vasculogenic hydrogels for improved islet engraftment; methods to conduct non-invasive monitoring of islet transplants; and development of immune acceptance protocols for free and encapsulated islet allografts and xenografts. Training specific to insulin delivery methods will focus on the engineering of microneedle technologies for glucose sampling and delivery of insulin, including microfabrication and biomaterials, ultimately as part of a closed loop artificial pancreas system. The research training program will encompass exposure to the clinical aspects of diabetes management and patient care, as well as the industrial aspects of biotechnology development and commercialization. Upon successful completion of the program, trainees will be prepared to move into leadership positions in industry and academia and develop new, cutting-edge technologies and therapies for diabetics aimed at improving the quality of life of patients and reducing the economic burden .on the diabetic population and the overall healthcare costs.

摘要 糖尿病计划：工程技术和治疗中的创新与领导(ILET^)是一个 在细胞和组织治疗和新型胰岛素方面独特的跨学科博士后培训计划 治疗胰岛素依赖型糖尿病(IDD)的给药技术。IDD是一个严重的健康问题，影响着 美国和世界各地数以百万计的人。与目前基于胰岛素注射或 开环胰岛素泵，新一代疗法有可能提供更少的侵入性，更多 对血糖水平进行生理性的、最终成本更低的调节，潜在地减少长期的 并发症和革命性的糖尿病护理。迫切需要进行跨学科的培训 生物工程师和生物科学家在与开发生物替代品相关的复杂问题上 β细胞替代和人工胰腺，包括基础科学、生物工程和 转化医学。 ILET？是佐治亚理工学院和埃默里大学学院的联合培训项目 医学部。该计划将通过为学员提供专业知识来培训这一领域的未来研究专家 在以下方面对推进下一代糖尿病治疗至关重要：1)发展能力 新的胰岛封装和植入系统，包括新的生物材料和工艺；2)能够 工程师对同种异体胰岛移植物和异种移植物的免疫接受；3)设计非β胰岛素的能力- 作为胰岛替代品的分泌生理反应细胞；4)开发新方法的能力 用于葡萄糖采样和将胰岛素输送到闭合的人工胰腺系统。以研究为基础 细胞疗法方面的培训将专门针对胰岛和其他胰岛素分泌的胶囊系统。 细胞；潜在的自体β细胞替代物的工程；血管生成的发展 改进胰岛移植的水凝胶；对胰岛移植进行非侵入性监测的方法；以及 为游离和包被的同种胰岛移植物和异种移植物开发免疫接受方案。 专门针对胰岛素给药方法的培训将侧重于微针技术的工程设计，以 胰岛素的葡萄糖采样和输送，包括微制造和生物材料，最终作为 闭环式人工胰腺系统。 研究培训计划将包括接触糖尿病管理的临床方面。 和病人护理，以及生物技术开发和商业化的工业方面。vt.在.的基础上 成功完成该计划，学员将准备进入行业的领导职位 和学术界，并为糖尿病患者开发新的尖端技术和疗法，旨在改善 患者的生活质量和减轻经济负担。对糖尿病人群和整体 医疗保健成本。